The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Frolov M.Yu.

Volgograd State Medical University;
Volgograd Medical Scientific Center

Salasyuk A.S.

Volgograd State Medical University

Rogov V.A.

Volgograd State Medical University;
Volgograd Research Medical Center

Astakhov S.Yu.

Pavlov First Saint Petersburg State Medical University

Pharmacoeconomic analysis of brolucizumab therapy in patients with neovascular age-related macular degeneration

Authors:

Frolov M.Yu., Salasyuk A.S., Rogov V.A., Astakhov S.Yu.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2021;43(4): 59‑71

DOI: 10.17116/medtech20214304159

Read: 1672 times

Download PDF (RU)
Contact the author
Table of contents

PHARMACOECONOMIC ANALYSIS OF BROLUCIZUMAB THERAPY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
PHARMACOECONOMIC ANALYSIS OF BROLUCIZUMAB THERAPY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

To cite this article:

Frolov MYu, Salasyuk AS, Rogov VA, Astakhov SYu. Pharmacoeconomic analysis of brolucizumab therapy in patients with neovascular age-related macular degeneration. Medical Technologies. Assessment and Choice. 2021;43(4):59‑71. (In Russ.)
https://doi.org/10.17116/medtech20214304159

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Biosimilars of rani­bizumab in reti­nal diseases: new possibilities in ophthalmology. Russian Annals of Ophthalmology. 2025;(2):106-116
New options dete­rmining the success of treatment for neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2025;(3):71-78
Algo­rithm for predicting treatment outcomes in vascular pigment epithelial deta­chment in neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2025;(4):12-18
Use of fari­cimab in neovascular age-related macu­lar dege­neration and diabetic macu­lar edema in Russia. Resu­lts of the FARWATER retrospective study. Russian Annals of Ophthalmology. 2025;(6):82-91
Analysis the frequency of using Afli­bercept (8 mg) in the treatment of neovascular age-related macu­lar dege­neration and diabetic macu­lar edema compared with other anti-VEGF agents. Russian Annals of Ophthalmology. 2025;(6):92-100
Abstract:

OBJECTIVE

Clinical and economic analysis of anti-VEGF therapy in adults with neovascular age-related macular degeneration (nAMD).

MATERIAL AND METHODS

We analyzed clinical efficacy of brolucizumab, aflibercept and ranibizumab for the treatment of nAMD in adults. Moreover, «cost minimization» for two scenarios of anti-VEGF therapy in the Russian Federation were assessed (taking into account the cost of anti-VEGF drugs only and intravitreal injections (IVI) within inpatient care with payment system based on disease-related groups (DRG)).

RESULTS

A. Skelly et al. (2020) performed a meta-analysis of brolucizumab, aflibercept and ranibizumab in adults with nAMD. They found that all drugs similarly influenced the maximum corrected visual acuity. However, brolucizumab required fewer injections compared to aflibercept and ranibizumab in any treatment regimens. Cost minimization analysis found that annual cost of brolucizumab therapy for one patient was lower by 36% compared to aflibercept and 35% compared to ranibizumab. After 2 years, this difference was 37% and 38% for aflibercept and ranibizumab, respectively. Cost minimization analysis for inpatient DRG-based care showed that annual cost of brolucizumab therapy for one patient was lower by 21% and 30% compared to aflibercept and ranibizumab, respectively. After 2 years, this difference was 22% and 32%, respectively. Analysis of sensitivity confirmed stable results in fluctuations of the «price of drugs» parameter within +/– 20% for scenario with calculation of medication cost only and the parameter «IVI frequency» within +/– 10% for scenario with calculation of cost of IVI within DRG.

CONCLUSION

Brolucizumab therapy in adults with nAMD leads to decrease in direct medical costs and volume of medical care compared to aflibercept and ranibizumab.

Keywords:

neovascular age-related macular degeneration
nAMD
anti-angiogenic therapy
anti-VEGF
brolucizumab
ranibizumab
aflibercept
intravitreal injections

Authors:

Frolov M.Yu.

Volgograd State Medical University;
Volgograd Medical Scientific Center

Salasyuk A.S.

Volgograd State Medical University

Rogov V.A.

Volgograd State Medical University;
Volgograd Research Medical Center

Astakhov S.Yu.

Pavlov First Saint Petersburg State Medical University

Received:

20.09.2021

Accepted:

14.10.2021

Close metadata

References:

  1. Pascolini D, Mariotti SP, Pokharel GP, Pararajasegaram R, Etya’ale D, Négrel AD, et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiology. 2004;11(2):67-115.  https://doi.org/10.1076/opep.11.2.67.28158
  2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990—2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196. https://doi.org/10.1016/S0140-6736(12)61729-2
  3. Wong WL, Su X, Li X, Cheung ChMG, Klein R, Cheng Ch-Yu, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet. Global Health. 2014;2(2):106-116.  https://doi.org/10.1016/S2214-109X(13)70145-1
  4. Vozrastnaya makulyarnaya degeneraciya. Klinicheskie rekomendacii. 2021. Accessed September 1, 2021. (In Russ.). https://cr.minzdrav.gov.ru/schema/114_2
  5. Pece A, Azzolini C, Parodi MB, Bottoni F, Danzi P, Donati S, et al. Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab. Expert Review of Ophthalmology. 2012;7(3):219-225.  https://doi.org/10.1586/eop.12.24
  6. Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116-126.  https://doi.org/10.1016/j.ophtha.2007.03.008
  7. Bikbov MM, Zainullin RM, Gilmanshin TR, Kazakbaeva GM, Rakhimova EM, Rusakova A, et al. Prevalence and Associated Factors of Age-Related Macular Degeneration in a Russian Population: The Ural Eye and Medical Study. American Journal of Ophthalmology. 2020;210:146-157.  https://doi.org/10.1016/j.ajo.2019.10.004
  8. Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, et al. 2018 update on intravitreal injections: Euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181-193.  https://doi.org/10.1159/000486145
  9. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Ejlea (aflibercept). Accessed January 21, 2021. (In Russ.). https://grls.rosminzdrav.ru/GRLS.aspx
  10. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Lucentis (ranibizumab). Accessed January 21, 2021. (In Russ.). https://grls.rosminzdrav.ru/GRLS.aspx
  11. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Vizk’yu (brolucizumab). Ssylka aktivna na 21.01.21. Accessed January 21, 2021. (In Russ.). https://grls.rosminzdrav.ru/GRLS.aspx
  12. Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus Aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296-1304. https://doi.org/10.1016/j.ophtha.2017.03.057
  13. Tadayoni R, Sararols L,Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101.  https://doi.org/10.1159/000513048
  14. Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127(7):963-976.  https://doi.org/10.1016/j.ophtha.2019.12.031
  15. Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Ophthalmology. 2016;123(5):1080-1089. https://doi.org/10.1016/j.ophtha.2015.12.030
  16. Dugel PU, Koh A, Ogura Yu, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72-84.  https://doi.org/10.1016/j.ophtha.2019.04.017
  17. Dugel PU, Singh RP, Koh A, Ogura Yu, Weissgerber G, Gedif K, et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89-99.  https://doi.org/10.1016/j.ophtha.2020.06.028
  18. Rasshifrovka kliniko-statisticheskih grupp dlya medicinskoj pomoshchi, okazannoj v stacionarnyh usloviyah 2021. Ssylka aktivna na 21.01.21. Accessed January 21, 2021. (In Russ.). https://www.ffoms.gov.ru/documents/the-orders-oms/
  19. Lipatov DV, Lyshkanets OI. Intravitreal therapy of diabetic macular edema in Russian Federation: current state of the problem. Vestnik oftal’mologii. 2019;135(4):128-139. (In Russ.). https://doi.org/10.17116/oftalma2019135041128
  20. Rasshifrovka kliniko-statisticheskih grupp dlya medicinskoj pomoshchi, okazannoj v usloviyah dnevnogo stacionara 2021. Accessed January 21, 2021. (In Russ.). https://www.ffoms.gov.ru/documents/the-orders-oms/
  21. Skelly A. Systematic literature review and network meta-analysis to assess brolucizumab in neovascular age-related macular degeneration. Study Report. 31st August 2020. Novartis Pharma AG. 
  22. Federal’naya antimonopol’naya sluzhba. Predel’nye razmery optovyh nadbavok i predel’nye razmery roznichnyh nadbavok k cenam na zhiznenno neobhodimye i vazhnejshie lekarstvennye preparaty, ustanovlennye v sub»ektah Rossijskoj Federacii (dannye na 10 fevralya 2020). Accessed October 10, 2021. (In Russ.). https://fas.gov.ru/documents/686367
  23. Ye L, Jiaqi Z, Jianchao W, Zhaohui F, Liang Y, Xiaohui Z. Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis. Therapeutic Advances in Chronic Disease. 2020;11:2040622320953349. https://doi.org/10.1177/2040622320953349
  24. Nedogoda SV, Salasyuk AS, Bobykin EV, Barykina IN, Smirnova VO., Popova EA. Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration. Rossijskij oftal’mologicheskij zhurnal. 2020;13(1):42-50. (In Russ.). https://doi.org/10.21516/2072-0076-2020-13-1-42-50
  25. Yu JS, Carlton R, Agashivala N, Hassan T, Wykoff CC. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. Journal of Managed Care and Specialty Pharmacy. 2021;27(6):743-752.  https://doi.org/10.18553/jmcp.2021.27.6.743
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.